HomeCase Study
Romanian Dialysis Market - Competition over 150 millions EUR

Is CaNaMed impact spilling beyond Romanian borders?
Each year April 1st reboots the rules of engagement for the Romanian pharm industry, for many reasons, such as the enactment of Framework Agreement or the update of the National Price Catalogue for prescription medication. April 1st brings also an opportunity for analysis and review of the impact on the environment in which pharma players are acting.
Solutions for the private health care sector in sourcing liquidity.
The case study will analyze the solution found by the suppliers and creditors of the public healthcare system in Italy and provide an assessment on the conditions under which similar proceedings could prove to be a viable solution in Romania’s case.
CLAWBACK - Either RO or HU is the lesser of the two "evils"?
Improving expenditure efficiency has been, for a very long time, a much desired objective for public health authorities all over Europe. Measures have been developed to address increase in consumption costs as well as to counteract pressure exerted by private suppliers on the public health systems.
« Previous
Next »
